Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) announced that the group had acquired a new research and development center, measuring close to 48,000 square feet; the facility is in Frederick.
Information about the recent acquisition
According to a source from the group, Tonix Pharmaceuticals Holding Corp’s recent purchase of the R&D facility will support the group’s various initiatives to treat infectious diseases.
Here is a list of initiatives that Tonix Pharmaceuticals Holding Corp is either working on or has completed
The team of experts at Tonix Pharmaceuticals Holding Corp have designed and developed the TNX-1800. It is a live virus vaccine that is used to give the user protection against the deadly COVID-19. Another live virus vaccine named TNX-801 is created to provide the patient with protection against smallpox and monkeypox. The TNX-3500, it is learned, is at present in the under-development stage. The small molecule antiviral, when developed, can be used to treat COVID-19. The TNX-2100 is another offering by the company used to test the immunity of the T cells in SARS-CoV-2.
Tonix Pharmaceuticals Holding Corp is working on creating vaccines that can help people deal with the COVID-19 pandemic
The team of experts at Tonix Pharmaceuticals Holding Corp is working on designing and developing solutions in vaccines and therapeutics to help people deal with the coronavirus pandemic. The President and Chief Executive Officer of the group, Seth Lederman, stated that acquiring the R&D center is an important milestone that the group has achieved. He added that this would pave the way for our team to strengthen work in the vaccines and antiviral therapeutics sectors and thus deliver superior productivity in this direction. Lederman added that the group is preparing to design and develop solutions for the various diseases, disorders, and conditions that could affect the population in the future.
The group works in the areas of immunology and the central nervous system (CNS)
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company that designs, develops, and introduces solutions to prevent and treat diseases and conditions that impact human beings. The company works in the areas of immunology and the central nervous system (CNS). The company tested its TNX-1800 candidate by performing research studies on animals. The group reported positive results. Phase 1 study involving human beings is scheduled to be completed in 1Q 2022.